Office of Cannabis Management required to establish limits on the total THC in cannabis flower and cannabis products; addition of ingredients to impart a taste or smell to cannabis products intended to be consumed through the inhalation of smoke, vapor, or aerosol prohibited; warnings about cannabis consumption required to include a warning regarding cancer; and advertisements prohibited that promote the co-consumption of alcohol and cannabis.

2025-2026 Regular Session Introduced by Kristin Robbins

Minnesota cannabis bill caps THC potency, bans inhalable flavor additives, requires cancer warnings, and restricts alcohol-cannabis co-promotion advertising.

Introduction and first reading, referred to Commerce Finance and Policy

#drugsandmedicine

Legislative bill overview

HF 755 establishes regulatory requirements for Minnesota's cannabis market, including: mandatory THC potency caps on flower and products, prohibition of flavor additives in inhalable cannabis, addition of cancer warnings to cannabis packaging, and restrictions on advertising that promotes simultaneous alcohol and cannabis use. The bill delegates implementation authority to the Office of Cannabis Management.

Why is this important

As Minnesota develops its legal cannabis market, this bill addresses public health concerns by limiting product potency, reducing inhalation appeal to new users (particularly youth), ensuring consumers understand serious health risks, and preventing marketing that could encourage dangerous polysubstance use. These measures reflect evolving state approaches to cannabis regulation based on emerging health data.

Potential points of contention

THC potency limits: Industry argues caps reduce consumer choice and push users to black markets; public health advocates support limits citing concerns about dependency and mental health effects, particularly in younger users

Flavor prohibition scope: Affects product diversity and consumer preferences; tobacco industry restrictions used similar logic, but cannabis market dynamics differ; questions remain about whether this drives consumption through other routes

Cancer warning specificity: Limited epidemiological evidence directly links cannabis smoking to cancer (unlike tobacco); warning may overstate current scientific consensus or create legal liability questions about comparative risk accuracy

Alcohol co-marketing restrictions: Raises First Amendment concerns about commercial speech; enforcement challenges in digital/social media environments; questions about whether restriction extends to owned-and-operated retail locations selling both products